Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."

About RXI-109

RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein an
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... 2014 Shire plc (LSE: ... specialty biopharmaceutical company, and ArmaGen, a US privately ... and collaboration agreement for AGT-182, an investigational enzyme ... both the central nervous system (CNS) and somatic ... This collaboration strengthens Shire,s rare disease pipeline of ...
(Date:7/23/2014)... California (PRWEB) July 23, 2014 With the ... in HD resolution for more than 15 minutes, Fastec Imaging ... the world of high speed imaging. “Finally, a high speed ... camera we use in our everyday lives.” proclaims Matt Kearney, ... Fastec has always been to demystify and simplify the traditionally ...
(Date:7/23/2014)... 2014 Astra Nova Training ... consultancy and pharma training services, and the ... , a non-profit integrating the expertise and investments ... a global system for clinical trials, are pleased ... the expertise of industry professionals through improved and ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... the Molecular Bioassays Market , , MOUNTAIN ... recent analysis of the molecular bioassays market, Frost ... Frost & Sullivan North America Technology Innovation of ... for cell surface receptor investigation, in particular G ...
... Case Studies and Patient Reported Outcome Strategies , ... the industry leader in electronic patient reported outcomes (ePRO) ... its 2009 ePROficiency(TM) Web seminar series on Patient Reported ... series is a continuation of invivodata,s educational initiative which ...
... MAO-B at Maximum Approved Dose , , KANSAS ... presented results from a clinical pharmacology study in which ... tyramine sensitivity at the maximum approved dose of 1 ... Congress of Parkinson,s Disease and Movement Disorders in Paris, ...
Cached Biology Technology:Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 2Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 3Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 4Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 5invivodata Announces ePROficiency 2009 Web Seminar Series 2Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity 2Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity 3Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity 4Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity 5
(Date:7/23/2014)... culinary herbs oregano and rosemary are packed with healthful ... in much the same way as prescription anti-diabetic medication, ... Journal of Agricultural and Food Chemistry , they ... difference, and they also identified which compounds contribute the ... Mejia and colleagues point out that in 2012, type-2 ...
(Date:7/23/2014)... degradation and blood-brain barrier damage appear after ... functioning. Matrix metalloproteinase-9 is able to degrade ... around cerebral blood vessels and to mediate ... and colleagues from the First Affiliated Hospital ... China induced cerebral infarction in stroke-prone spontaneously ...
(Date:7/23/2014)... the brain is important for encoding environment ... mechanisms are unclear. Dr. Zhouyan Feng and ... activity of hippocampal neurons in rats using ... the neuronal responses. Somatosensory stimulation, in the ... potentials into theta rhythm-dominated waveforms, decreased the ...
Breaking Biology News(10 mins):
... biologists at Rutgers, Waksman Institute of Microbiology are ... an unassuming name. Now they have convinced the ... tremendous potential for cleaning up pollution, combating global ... builds upon Rutgers, burgeoning energy and environmental research ...
... in Spanish . , Barcelona, Spain: Research ... women undergo assisted reproduction technology (ART) shows that for younger ... two attempts, whereas women over the age of 40 had ... throughout their first four attempts. Mr Simon Hong ...
... available in Spanish . , Barcelona, Spain: ... into an egg to fertilise it, is increasingly used to ... the procedure may appear quite normal, researchers in the US ... damage, which can decrease the chances of pregnancy. Mr. ...
Cached Biology News:Duckweed genome sequencing has global implications 2Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle 2Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle 3Normal-looking sperm may have serious damage; scientists urge more care in selection 2Normal-looking sperm may have serious damage; scientists urge more care in selection 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Normal serum collected from healthy Kunming mice....
Request Info...
Biology Products: